Scholars Central

Conference abstractPublished 3 Nov 2016

New therapies for GI cancer under the track gastrointestinal oncology

Authors: Zubair A khan

GI & LIVER Clinic Doost Medical Complex Multan, Pakistan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

New treatments are emerging in field of gastroenterology oncology and it includes advancements in gastroesophageal colorectal, pancreatic and anal canal carcinomas. FDA has approved angiogenesis inhibitor ramuciromab in unresectable, advanced or metastatic gastric and gastroesophageal junction tumors after therapy with fluoropyrimidines and platinum drugs. Trastuzumab is approved for locally advanced and metastatic HER-2neu positive gastroesophageal cancer only and PD-1 inhibitor, pembrolizumab, in heavily pre-treated patients with metastatic gastric cancer. The major findings were that it is feasible. In terms of toxicity, it is feasible with pembrolizumab to achieve a decrease in tumor size. Adjuvant imatinib has become a standard treatment in all patients with significant risk for recurrence after resection of primary GISTs. FDA also approved erlotinib hydrochloride in combination with gemcitabine for the treatment of patients with locally advanced, unresectable or metastatic pancreatic carcinoma. In colon cancer, the antiangiogenic agent bevacizumab is approved in combination with other agents. EGFR-1 (epidermal growth factor receptor 1) signaling pathway is thought to play a pivotal role in tumor growth and progress of colorectal cancer. Cetuximab targets an epidermal growth factor receptor (EGFR), which is found in about 80 percent of colorectal cancers and itâÂ?Â?s effective in patients with NO K-ras mutation. Erbitux is effective even if EGFR is not found in an individual tumor. In treatment of anal canal cancer traditionally treated with abdominoperineal resection, resulting in high rates of morbidity and local recurrence. Pioneering work led to the finding that radiation therapy (RT) combined with 5-fluorouracil (5-FU) and mitomycin results in high rates of local control and disease-free and colostomyfree survival without surgery.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Gastrointestinal & Digestive System.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Gastrointestinal & Digestive System
  • SubjectGastroenterology & Hepatology
  • BylineArticles whose byline prints “Zubair A khan”